Cowen & Co. Maintains a Buy Rating on Alexion Pharmaceuticals (ALXN)


In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Alexion Pharmaceuticals (ALXN), with a price target of $165. The company’s shares opened today at $135.22, close to its 52-week high of $140.77.

According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 8.3% and a 51.0% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Allogene Therapeutics Inc.

Currently, the analyst consensus on Alexion Pharmaceuticals is a Strong Buy with an average price target of $161.67.

See today’s analyst top recommended stocks >>

Based on Alexion Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $45 million. In comparison, last year the company earned revenue of $941 million and had a net profit of $30 million.

Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P.